A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

692

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

RADIATION: Radiotherapy
DRUG: LHRHa
DRUG: Apalutamide

Sponsor

Janssen Pharmaceutica N.V., Belgium